Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
6-Prenylnaringenin (6-PN) is a naturally occurring prenylated flavonoid found primarily in hops (*Humulus lupulus*) and beer. It is an isomer of the potent phytoestrogen 8-prenylnaringenin (8-PN). Unlike 8-PN, 6-prenylnaringenin exhibits very weak estrogenic activity, making it an attractive candidate for non-hormonal therapeutic applications. It acts as a potent and reversible blocker of T-type voltage-gated calcium channels (specifically Cav3.2), a positive allosteric modulator of GABAA receptors, and an agonist of the aryl hydrocarbon receptor (AhR). Research has demonstrated its potential in alleviating neuropathic and visceral pain, inhibiting histone deacetylases (HDACs) to exert antiproliferative effects against various cancer cell lines (such as melanoma and prostate cancer), and promoting estrogen detoxification by inducing CYP1A1 expression. Clinical evaluation has focused on its safety, pharmacokinetics, and bioavailability, including the use of micellar solubilization to enhance its oral absorption.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 6-prenylnaringenin.